Abstract

BackgroundIn recent years, immunotherapy has advanced the cancer field by achieving more durable patient response with a relatively tolerable toxicity. However, the overall response rates remain low (< 20%),1 mainly...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call